Phaseline

Companies › CanariaBio

CanariaBio: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Oregovomab
Mucin-16 other
MUC16Phase 3Carcinoma, Ovarian Epithelial; Recurrent Ovarian Cancer; Ovarian Neoplasm Epithelial; Ovarian Cancer by FIGO StageDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04938583OregovomabPhase 1Ovarian Cancer by FIGO StageOncologyOct 2025
NCT04498117OregovomabPhase 3Carcinoma, Ovarian EpithelialOncologyDec 2026
NCT05335993OregovomabPhase 2Recurrent Ovarian CancerOncologyDec 2026
NCT05605535OregovomabPhase 2Ovarian Neoplasm EpithelialOncologyMay 2027

Targets

MUC16 (1)

Companies with the same targets

Beijing Biotech Regeneron Pharmaceuticals Whitehawk Therapeutics

Companies built like this

Maia Biotechnology K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals FutureGen Biopharmaceutical (Beijing) Epizyme pharmaand

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.